GLP-1 Users Face Measurable Rise in Summer Dehydration Risk from Suppressed Thirst

The Healthline report draws on UK clinician Clare Thompson describing reduced fluid intake from nausea and absent thirst cues, plus blood-pressure lowering that compounds orthostatic effects in heat. Observational data from post-marketing surveillance of semaglutide show gastrointestinal adverse events in 15-20% of users, indirectly raising dehydration markers such as elevated serum creatinine. No dedicated RCT has quantified summer-specific incidence, leaving absolute risk elevation unmeasured against background rates of 5-8% heat-related ED visits in adults over 45. Storage warnings remain secondary but critical, as temperatures above 30°C degrade peptide stability within hours. Patterns from SGLT2 inhibitor literature suggest similar fluid-balance vulnerabilities were initially under-recognized until large cohort studies emerged two years post-approval. GLP-1 users may therefore encounter analogous surveillance gaps this season, especially among those combining agents or living in urban heat islands. Mitigation hinges on scheduled electrolyte intake rather than ad-hoc water consumption, a behavior change unsupported by current labeling.